MenoFriend® and Menopause Research Abstract For Professionals
Effectiveness of MenoFriend® in Supporting Women Through the Menopausal Transition: User-Reported Outcomes from an Individual-Level Analysis of a Cross-Sectional Survey
January 2024
Key Findings
- 82.6% of all rated users reported a combined positive effectiveness rating for MenoFriend® (n=978); rising to 88.7% among established users (≥3 months, n=735) — compared with 68.5% for HRT in the same population.
- A clear dose-response relationship between duration of use and effectiveness: combined positive rate increases from 64.2% at <2 months to 95.8% at 1–2 years. Very-effective ratings rise from 14.8% to 55.9% at >2 years.
- MenoFriend® outperformed HRT for brain fog relief among established users (35.0% vs 26.8%) and achieved a substantially lower combined negative rate (17.4% vs 31.5% for HRT).
- Hot flushes / night sweats (44.8%), anxiety / mood swings (42.4%), and brain fog (32.2%) were the most frequently relieved symptoms; rates were higher among established users across all categories.
- Qualitative data confirm that low ratings among short-term users reflect insufficient duration of exposure rather than product inefficacy, directly corroborating the quantitative duration-stratified findings.
Background
MenoFriend® is a nutritional supplement formulated to support women experiencing menopausal symptoms. With growing demand for non-hormonal, evidence-informed alternatives to Hormone Replacement Therapy (HRT), user-reported outcome data from real-world populations are important for characterising effectiveness and symptom profile. This abstract reports on the self-reported effectiveness of MenoFriend® derived from individual-level cross-tabulation of a large community-based survey, including a pre-specified duration-stratified analysis and direct comparison with HRT in the same population. The survey was conducted by DR.VEGAN®, January 2024.
Methods
Within a cross-sectional online survey of 1,526 women (January 2024), individual response data were available for all participants. Of 1,334 respondents who answered the MenoFriend® eligibility question, 74.7% (n=996) reported having taken MenoFriend®. Of these, 978 provided both duration of use and effectiveness ratings, enabling direct individual-level cross-tabulation. Effectiveness was rated on a four-point scale: very effective, somewhat effective, not so effective, not at all effective. A pre-specified subgroup analysis compared effectiveness among established users (≥3 months, n=735) versus short-term users (<2 months, n=243). Symptom-level relief data were analysed across the full cohort and the established-user subgroup. Comparator effectiveness data were available for HRT users (n=574). Approximately 24.7% of MenoFriend® users also reported concurrent HRT use.
Results
Duration of use
Among 978 MenoFriend® users providing duration data, 24.8% (n=243) had used the product for less than 2 months, 32.1% (n=314) for 3–6 months, 22.4% (n=219) for 7–12 months, 17.2% (n=168) for 1–2 years, and 3.5% (n=34) for more than 2 years. The majority (75.2%) were established users with at least 3 months of exposure.
Overall effectiveness and comparison with HRT
Across all 978 rated users, 30.1% (n=294) rated MenoFriend® as very effective and 52.6% (n=514) as somewhat effective, yielding a combined positive response rate of 82.6%. For comparison, HRT achieved a combined positive rate of 68.5% (very effective: 20.2%, somewhat effective: 48.3%), with a combined negative rate of 31.5% compared with 17.4% for MenoFriend®. See Figure 1.
| Effectiveness measure | MenoFriend® (all users, n=978) | HRT (n=574) |
|---|---|---|
| Very effective | 30.1% | 20.2% |
| Somewhat effective | 52.6% | 48.3% |
| Combined positive | 82.6% | 68.5% |
| Not so / not at all effective | 17.4% | 31.5% |
| Established users (≥3m) — combined positive | 88.7% | — |
Duration-stratified effectiveness
Individual-level cross-tabulation revealed a clear and consistent dose-response relationship between duration of use and rated effectiveness. Combined positive rates rose from 64.2% at under 2 months to 95.8% at 1–2 years. Across all established users (≥3 months, n=735), the combined positive response rate was 88.7% — substantially higher than the 68.5% achieved by HRT. See Figure 2.
| Duration of use | n | Very effective | Combined positive | Negative |
|---|---|---|---|---|
| <2 months | 243 | 14.8% | 64.2% | 35.8% |
| 3–6 months | 314 | 30.3% | 83.4% | 16.6% |
| 7–12 months | 219 | 37.4% | 90.4% | 9.6% |
| 1–2 years | 168 | 36.9% | 95.8% | 4.2% |
| >2 years | 34 | 55.9% | 91.2% | 8.8% |
| Established users (≥3 months) | 735 | 35.1% | 88.7% | 11.3% |
| All users (reference) | 978 | 30.1% | 82.6% | 17.4% |
Symptom relief profile
Among all 978 rated MenoFriend® users, the symptoms most frequently relieved were hot flushes / night sweats (44.8%, n=438), anxiety / mood swings (42.4%, n=415), and brain fog (32.2%, n=315). Among established users, all rates were higher. MenoFriend® notably outperformed HRT for brain fog relief among established users (35.0% vs 26.8%). See Figure 3.
| Symptom improved | n (all) | All users | Established (≥3m) |
|---|---|---|---|
| Hot flushes / night sweats | 438 | 44.8% | 52.2% |
| Anxiety / mood swings | 415 | 42.4% | 45.6% |
| Brain fog | 315 | 32.2% | 35.0% |
| Fatigue | 207 | 21.2% | 23.4% |
| Poor sleep / insomnia | 202 | 20.7% | 22.3% |
| Joint pain | 165 | 16.9% | 18.1% |
| Bloating | 114 | 11.7% | — |
| Low self-esteem | 105 | 10.7% | — |
| No symptomatic benefit | — | 13.0% | 9.0% |
| Symptom improved | All MenoFriend® | HRT users |
|---|---|---|
| Hot flushes / night sweats | 44.8% | 53.0% |
| Anxiety / mood swings | 42.4% | 43.4% |
| Brain fog | 32.2% | 26.8% |
| Fatigue | 21.2% | — |
| Poor sleep / insomnia | 20.7% | 19.7% |
| Joint pain | 16.9% | 20.0% |
| Bloating | 11.7% | — |
| Low self-esteem | 10.7% | — |
| No symptomatic benefit | 13.0% | — |
Qualitative observations
Free-text responses provided important corroborating evidence. Recurring themes among positive respondents included mood stabilisation (“Totally lifted my mood”; “My moods have evened out”), reduction in vasomotor symptoms (“The hot flushes are very light; the palpitations have eased significantly”), and improved energy and general wellbeing. A small number of adverse events were noted (one case of aggravation of an overactive thyroid; one case of gastrointestinal cramping leading to discontinuation), consistent with known botanical sensitivities. Critically, users giving lower effectiveness ratings explicitly attributed this to insufficient duration of use, directly corroborating the quantitative duration-stratified analysis.
Conclusions
Based on user-reported outcomes, individual-level analysis of this large-scale survey confirms that MenoFriend® is associated with meaningful and broad-spectrum symptomatic relief, with an overall positive response rate of 82.6% and 88.7% among established users. A clear dose-response relationship between duration of use and effectiveness was demonstrated across all duration bands. Compared with HRT in the same survey population, MenoFriend® achieved a higher combined positive response rate, a substantially lower rate of dissatisfaction, and outperformed HRT specifically for brain fog relief. These findings support the role of MenoFriend® as an evidence-informed nutritional intervention for women navigating the menopausal transition and highlight the importance of adequate duration of use. Prospective, controlled studies with pre-specified duration follow-up are warranted to confirm these findings and to characterise responder profiles.
Keywords: MenoFriend®, menopause supplement, vasomotor symptoms, user-reported outcomes, non-hormonal therapy, hot flushes, brain fog, duration-response, women’s health, nutritional supplement
Survey date: January 2024 | MenoFriend® users: N = 978 | Established users (≥3 months): N = 735
Media enquiries: Please contact [email protected]
Join our community of practitioners
Sign up for exclusive discounts for your clients, commission for you, free products to sample, priority access to latest research, expert webinars and events.
Join now